Auspherix Limited (UK)
Stevenage Bioscience Catalyst
Gunnels Wood Road
Stevenage
Herts
SG1 2FX
United Kingdom
Tel: 44-0-1438-906755
Website: http://auspherix.com/
Email: info@auspherix.com
About Auspherix Limited (UK)
Auspherix is a pre-clinical stage anti-infectives company initially founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS) by Professor Ian Charles and Dr Dagmar Alber.Auspherix is now located in the UK and operates from offices and research labs in the Stevenage Bioscience Catalyst facility. The Company is building a world class microbiology team to progress its R&D programmes based on its proprietary antibacterials, which have a unique profile. Its compound series show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections.
YEAR FOUNDED:
2014
LEADERSHIP:
CEO: Dr. Neil Miller
COO: Grant Hawthorne
CSO: Dr. Richard Rutter
Head of Chemistry: Dr. Paul King
CAREER:
Please click here for Auspherix's job opportunities.
5 articles about Auspherix Limited (UK)
-
Auspherix Awarded Innovate UK Grant to Test its Organogold Antibiotics to Treat Life-Threatening Respiratory Infections
2/12/2018
The Company is already progressing its lead programme, focused on the treatment of complicated urinary tract infection, through pre-clinical studies.
-
Auspherix Presents Pharmacokinetic-Pharmacodynamic (PK/PD) Profile of Its Antibacterial Compounds in Rodents
10/20/2017
Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, today announced that it is presenting proprietary bioanalytical methods to characterise the in vivo pharmacokinetic profile and PK/PD relationship of its compounds, following systemic dosing in rodents.
-
Auspherix To Present Organogold Pipeline At Superbugs & Superdrugs
3/20/2017
-
Auspherix Provides Update On Its New Class Of Organogold Antibiotics
1/5/2017
-
Management Team Strengthened As Auspherix Drives New Class Of Antibacterials Towards The Clinic
11/17/2016